Interest-Based Ads

Here’s what goes on with relapsing MS:

The immune system uses certain cells, like B cells, to help fight infections. These cells can become activated in the lymph nodes—the communication hub for the immune system.

But there’s a miscommunication that happens in relapsing MS. Instead of protecting the immune system, these cells mistakenly attack the body’s myelin—the fatty, protective covering of the nerves in the brain and spinal cord.

Here’s what KESIMPTA does:

Although it’s not known exactly how KESIMPTA works in relapsing MS, it’s thought to travel specifically to the lymph nodes based on the way it’s taken. From there, it’s believed to reduce the number of B-cells that are thought to play a role in relapsing MS.

See how KESIMPTA works here.

This targeted approach to the lymph nodes is thought to limit the impact on other B-cells your body needs to maintain immune function.

KESIMPTA is a once monthly* treatment with at-home flexibility and proven results for reducing relapses and active lesions and slowing disability progression.^† It has a similar overall safety profile to AUBAGIO® (teriflunomide).^‡

See the results here.

Talk to your doctor to find out if KESIMPTA may be right for you.

*Once monthly after 3 weekly starter doses.
^†Reduced annual rate of relapses by 51% and 58%, reduced average number of Gd+ T1 lesions per MRI by 98% and 94%, reduced disability progression by 34% at 3 months and 32% at 6 months in 2 studies vs AUBAGIO.
^‡AUBAGIO is a registered trademark of Genzyme, a Sanofi company.

Don't take KESIMPTA if you:

• have an active Hepatitis B Virus (HBV) infection.

• have had an allergic reaction to ofatumumab, or a life-threatening injection-related reaction to KESIMPTA.

KESIMPTA could increase the risk of serious, including life-threatening or fatal, infections:

• Hepatitis B virus (HBV) reactivation: Before starting KESIMPTA, you'll get a blood test for HBV. If you've ever had HBV infection, it may become active again during or after treatment with KESIMPTA

• Progressive multifocal leukoencephalopathy (PML): PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks, and can result in death or severe disability. While no cases of PML were reported in RMS clinical trials with KESIMPTA, it could happen.

• Weakened immune system: Taking KESIMPTA before or after other medicines that weaken your immune system could increase your risk of getting infections

Other serious side effects are:

• Local injection-site reactions: Symptoms include redness, swelling, itching, and pain.

• Injection-related reactions (systemic): Symptoms include fever, headache, pain in the muscles, chills, tiredness, rash, hives, trouble breathing, swelling of the face, eyelids, lips, mouth, tongue and throat, and feeling faint, or chest tightness.

• Low immunoglobulins: KESIMPTA may decrease some types of antibodies. Your doctor will do blood tests to check your immunoglobulin levels.

See full Important Safety Information here.

• Upper respiratory infections: Symptoms include sore throat, runny nose, and headache.

• Headache

See more details here.

Everyone reacts to medications differently. Talk with your doctor about any possible side effects and if KESIMPTA is right for you.

It is not known if KESIMPTA passes into breast milk. Talk to your doctor about the best way to feed your baby if you take KESIMPTA.

It is not known if KESIMPTA will harm your unborn baby. Tell your doctor if you're pregnant, think you might be pregnant, or plan to become pregnant before starting KESIMPTA. To help us better understand the effects of the treatment, there is a registry for women who become pregnant during treatment with KESIMPTA. For more information or to register, visit MotherToBaby ↗, call 1-877-311-8972 or send an email to [email protected] ↗.

It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control during treatment with KESIMPTA and for 6 months after your last treatment. Talk to your doctor about what birth control method is right for you during this time. To help us better understand the effects of the treatment, there is a registry for women who become pregnant during treatment with KESIMPTA. For more information or to register, visit MotherToBaby ↗, call 1-877-311-8972 or send an email to [email protected] ↗.

Yes, to help us better understand the effects of KESIMPTA, there is a registry for women who become pregnant during treatment with KESIMPTA. For more information or to register, visit MotherToBaby ↗, call 1-877-311-8972 or send an email to [email protected] ↗.

You shouldn’t receive any live vaccines while taking KESIMPTA and until your doctor tells you that your immune system is no longer weakened. Any required live vaccines should be received at least 4 weeks before you start KESIMPTA. If possible, any “non-live” vaccines should be received at least 2 weeks before you start treatment with KESIMPTA.

You can become a KESIMPTA Crew Member by calling 1-877-879-0245 or emailing us at [email protected].

Yes! You can find us on Facebook ↗, Instagram ↗, and YouTube ↗.

Yes! You can take KESIMPTA at home or wherever you go with a cooler or refrigerator. It's important to keep the KESIMPTA Sensoready® Pen between 2 °C to 8 °C (36 °F to 46 °F). Keep the pen in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. Also, don't forget to pack your sharps container, alcohol swabs, and cotton balls. If needed, KESIMPTA may be stored for up to 7 days at room temperature, up to 86 °F (30 °C). If stored below 86 °F (30 °C), unused KESIMPTA may be returned to the refrigerator and must be used within the next 7 days. If not used within those 7 days, discard the medicine.

You can store the KESIMPTA Sensoready® pens in a cooler or refrigerator. It's important to keep the KESIMPTA Sensoready Pen between 2 °C to 8 °C (36 °F to 46 °F). Keep the product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If needed, KESIMPTA may be stored for up to 7 days at room temperature, up to 86 °F (30 °C). If stored below 86 °F (30 °C), unused KESIMPTA may be returned to the refrigerator and must be used within the next 7 days. If not used within those 7 days, discard the medicine.

Before starting KESIMPTA, you'll get a blood test for hepatitis B virus (HBV). If you've ever had HBV infection, it may become active again during or after treatment with KESIMPTA. Your doctor will also have you get blood tests to check your immunoglobulin levels because KESIMPTA may decrease some types of antibodies.

You’ll be screened for HBV before starting KESIMPTA because if you’ve had HBV in the past, there’s a chance KESIMPTA can reactivate it. You’ll get a simple blood test to be sure.

You’ll give yourself 1 dose per week for the first 3 weeks, and then you’ll skip a week. After that, you can move on to 1 dose per month.

Someone from your health care team will give you guidance on how to take KESIMPTA for the first time.

If you need a refresher on how to take KESIMPTA, you can watch a demo video and learn more here. There are also downloadable resources and quick tips available here.

You can also ask your Alongside™ KESIMPTA Coordinator to set up an additional online demo.

Call 1-855-KESIMPTA (1-855-537-4678), 8:30 ᴀᴍ-8:00 ᴘᴍ ET, Monday-Friday.

Someone from your health care team will give you guidance on how to take KESIMPTA for the first time. After that, you can take KESIMPTA at home or wherever you go with a cooler or refrigeration. If you are taking KESIMPTA away from home, you’ll need to bring your sharps container, alcohol swabs, and cotton balls. It’s important to keep the KESIMPTA Sensoready® Pen between 36 °F and 46 °F and in its original carton until you are ready to use it. Do not freeze. To avoid foaming, do not shake.

If you miss an injection of KESIMPTA at Week 0, 1, or 2, talk to your doctor. If you miss a monthly injection, take it as soon as possible without waiting until the next scheduled dose. After that, take your KESIMPTA injections a month apart.

Check out how to take KESIMPTA here.

The best way is to use an FDA-cleared sharps container.

Ask your Coordinator how to get one for free. You’ll get a pre-paid return label to send your full sharps container back, and you’ll be sent a new container.

You shouldn’t throw away your Sensoready® Pen in your household trash. If you don’t have an FDA-cleared sharps container, you can use a household container that is:

• made of a heavy-duty plastic,

• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,

• upright and stable during use,

• leak-resistant, and

• properly labeled to warn of hazardous waste inside the container

Yes! It’s called Alongside™ KESIMPTA, and every KESIMPTA prescription comes with a membership. Members receive personalized support from a dedicated Coordinator who can determine if you’re eligible to save on KESIMPTA, and help you learn how to take it.

See how Alongside KESIMPTA has your back here, and become a member if you have a prescription but aren’t enrolled yet.

Everyone reacts to KESIMPTA a little differently, but it’s not uncommon to feel injection-related reactions within 24 hours after your first dose. These reactions may include fever, headache, muscle pain, chills, and fatigue, but generally decrease with each KESIMPTA dose. Reactions at or near the injection site include redness of the skin, swelling, itching, and pain. For more information on KESIMPTA reactions, please visit our safety page here.

Alongside KESIMPTA is a membership that comes with every KESIMPTA prescription. Members receive personalized support from a dedicated Coordinator who can determine if you’re eligible to save on KESIMPTA, and help you learn how to take it.

See what Alongside KESIMPTA can do here and become a member if you have a prescription but aren’t enrolled yet.

Here’s what happens next:

• We’ll help you get started by figuring out delivery and savings, including if you’re eligible to pay as little as $0^§ co-pay once you are covered

• We’ll mail you a welcome package with some important details inside

• You’ll get a dedicated Coordinator who will answer any questions throughout your membership

Get in touch at 1-855-KESIMPTA (1-855-537-4678 ↗), 8:30 ᴀᴍ–8:00 ᴘᴍ ET, Mon–Fri.

^§Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual co-pay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at start.kesimpta.com.

Yes—injection demonstrations are available. Choose from virtual demos or this demo video.

Keep in mind these demos do not replace any instructions provided by your doctor. If you have any questions, please get in touch with your doctor.

To schedule a demo or to get a Sensoready® Training Pen, call 1-855-KESIMPTA (1-855-537-4678), 8:30 ᴀᴍ–8:00 ᴘᴍ ET, Mon–Fri.

Your Alongside KESIMPTA Coordinator will identify the correct coverage assistance options to meet your needs. If you’re commercially insured and have coverage for KESIMPTA, they can enroll you in a $0 Co-pay Program.^§

If you are not covered for KESIMPTA, Coordinators will provide support to your doctor as your doctor pursues an appeal with your health care plan.

^§Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual co-pay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at start.kesimpta.com.

You can reach the Alongside KESIMPTA Support Team by calling:

1-855-KESIMPTA (1-855-537-4678)
8:30 ᴀᴍ–8:00 ᴘᴍ ET, Mon–Fri

Relapsing multiple sclerosis is a disease that affects the central nervous system (CNS), which is composed of the brain and spinal cord. The myelin, which protects the nerves in the CNS, gets damaged, and results in a variety of symptoms. A relapse is when new symptoms occur or when existing symptoms worsen.

CIS is the first occurrence of neurological symptoms that lasts a minimum of 24 hours. It is caused by inflammation of loss of myelin, which protects the nerves in the central nervous system (CNS).

RRMS describes the condition of experiencing cycles of relapses followed by periods of remission. RRMS is the most common form of relapsing MS.

Active SPMS is the early stage of SPMS, in which people experience fewer relapses but don't bounce back as well between relapses, and have increased disability. Active SPMS means a person may have had at least 1 relapse in the last 2 years.

The symptoms associated with RMS are variable and unpredictable. Every individual with RMS may experience a different variety and pattern of symptoms over time.

As the symptoms of RMS vary from person to person, there are no specific early signs of RMS.

The cause of RMS is unknown, and multiple factors are still being studied.

Although there is no cure for RMS, there are a variety of treatment options on the market that differ in efficacy, side effects, and dosing and administration. The treatments are administered through different methods such as injections, infusions, or pills. Medications, called disease-modifying therapies, or DMTs, don’t generally treat daily symptoms. Studies show that DMTs may help reduce relapses and slow disability progression.

A neurologist typically diagnoses and treats patients with RMS.

There is no single way to diagnose RMS. Your doctor can perform a variety of tests to rule out other conditions including a neurologic exam, an MRI, spinal fluid analysis, and blood tests. For more information on diagnosis, click here ↗.